(R)-VID400 | 174262-10-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-VID400
• 英文别名: 2-(R)-4'-chlorobiphenyl-4-carboxylic acid (2-imidazol-1-yl-2-phenyl-ethyl)-amide；N-[4-(4-Chlorophenyl)benzoyl]-2-(1H-imidazol-1-yl)-2(R)-phenyl-1-aminoethane；(1,1'-Biphenyl)-4-carboxamide, 4'-chloro-N-((2R)-2-(1H-imidazol-1-yl)-2-phenylethyl)-；4-(4-chlorophenyl)-N-[(2R)-2-imidazol-1-yl-2-phenylethyl]benzamide
• CAS: 174262-10-3
• 化学式: C₂₄H₂₀ClN₃O
• 分子量: 401.895
• InChiKey: FHHNSSGZEIVGMS-QHCPKHFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  46.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  咪唑 、 2-(4'-chlorobiphenyl-4-yl)-5(S)-phenyl-4,5-dihydro-oxazole 以 水 、 乙酸乙酯 、 甲苯 为溶剂， 生成 (R)-VID400
  参考文献：
  名称：

  Acylated aminoalkanimidazoles and - triazoles

  摘要：

  这项发明涉及式为##STR1##的唑类化合物，其中取代基具有各种意义，以自由形式或盐形式存在。它们可以通过酰化或通过环氧丙烷或噁唑环开启等方法制备。这些化合物可用作药物，特别是作为选择性抑制剂，用于治疗维生素D响应组织中增殖和分化紊乱的25-羟基维生素D3-羟化酶。

  公开号：

  US05622982A1

文献信息

• Acylated aminoalkanimidazoles and -triazoles
  申请人：SANDOZ LTD.

  公开号：EP0683156A1

  公开（公告）日：1995-11-22

  The invention concerns azole compounds of formula wherein the substituents have various significances, in free form or salt form. They can be prepared e.g. by acylation, or by aziridine or oxazole ring opening. The compounds can be used as pharmaceuticals, especially as selective inhibitors of the 25-hydroxyvitamin D3 - hydroxylases in the treatment of disorders of proliferation and differentiation in vitamin D - responsive tissues.

  本发明涉及式如下的唑类化合物 其中的取代基具有各种意义，以游离形式或盐形式存在。 它们可以通过酰化、氮丙啶或噁唑开环等方法制备。 这些化合物可用作药物，特别是作为 25-羟基维生素 D3-羟化酶的选择性抑制剂，用于治疗维生素 D 反应组织的增殖和分化障碍。
• Methods useful for vitamin D deficiency and related disorders
  申请人：OPKO RENAL, LLC

  公开号：US10302660B2

  公开（公告）日：2019-05-28

  Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders, related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin D deficiency or with susceptibility for catabolism-related vitamin D deficiency. In response to abnormally elevated CYP24 expression and/or activity, the method further includes administering a CYP24 inhibitor to the vitamin D deficient or at-risk patient, and preferably avoiding activation of the vitamin D binding receptor, such as by avoiding administration of active vitamin D compounds to such patients. Optionally, a vitamin D prohormone or prohormone can be administered.

  本发明公开了用于诊断、治疗和预防代谢相关维生素 D 缺乏症及相关疾病的方法、相关组合物、仪器和试剂盒。一种方法包括测量患者体内 CYP24 的表达和/或活性，或其替代物，如 FGF23 水平，并将异常升高的 CYP24 表达和/或活性与分解代谢相关维生素 D 缺乏症或分解代谢相关维生素 D 缺乏症的易感性相关联。针对异常升高的 CYP24 表达和/或活性，该方法进一步包括向维生素 D 缺乏或高危患者施用 CYP24 抑制剂，并优选避免激活维生素 D 结合受体，例如避免向此类患者施用活性维生素 D 化合物。可选地，可以施用维生素D原或维生素D原激素。
• METHODS, COMPOSITIONS, USES, AND KITS USEFUL FOR VITAMIN D DEFICIENCY AND RELATED DISORDERS
  申请人：Opko Ireland Global Holdings, Ltd.

  公开号：EP2281058B1

  公开（公告）日：2016-06-29
• Methods Compositions, Uses, and Kits Useful for Vitamin D Deficiency and Related Disorders
  申请人：Petkovich P. Martin

  公开号：US20110052567A1

  公开（公告）日：2011-03-03

  Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders; related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin D deficiency or with susceptibility for catabolism-related vitamin D deficiency. In response to abnormally elevated CYP24 expression and/or activity, the method further includes administering a CYP24 inhibitor to the vitamin D deficient or at-risk patient, and preferably avoiding activation of the vitamin D binding receptor, such as by avoiding administration of active vitamin D compounds to such patients. Optionally, a vitamin D prohormone or prohormone can be administered.
• Methods Useful for Vitamin D Deficiency and Related Disorders
  申请人：Opko Renal, LLC

  公开号：US20150141385A1

  公开（公告）日：2015-05-21

  Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders, related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin D deficiency or with susceptibility for catabolism-related vitamin D deficiency. In response to abnormally elevated CYP24 expression and/or activity, the method further includes administering a CYP24 inhibitor to the vitamin D deficient or at-risk patient, and preferably avoiding activation of the vitamin D binding receptor, such as by avoiding administration of active vitamin D compounds to such patients. Optionally, a vitamin D prohormone or prohormone can be administered.